Head-to-head · WeighScore
Immortals vs Iron Med RX
The verdict
Immortals takes it — 61.8/100 to 54.8/100.
Immortals grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Immortals is a LegitScript-certified longevity telehealth platform founded by Bryan Johnson, offering compounded semaglutide (Semaglutide/Glycine/B12) and tirzepatide (Tirzepatide/Glycine/B12) as microdose…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Immortals | Iron Med RX |
|---|---|---|
| WeighScore | 61.8/100 | 54.8/100 |
| Grade | C | C |
| Scorecard rank | #284 | #453 |
| Semaglutide | $167/mo (microdose tier, compounded) | Not disclosed |
| Tirzepatide | $180/mo (microdose tier, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #284 · C
Strengths
- LegitScript certified (ID 50458743) with board-certified U.S. physician review within 72 hours
- Physician consult + prescription bundled in price — 'You pay for treatment. That's it' with no added fees
- Competitive pricing: semaglutide microdose from $167/month, tirzepatide from $180/month (promotional)
- Unlimited provider messaging for 12 months included; video consults available
- Founded by Bryan Johnson and Kate Tolo; clinical lead Dr. Carl Seger, M.D. (preventive/longevity medicine)
Where it loses points
- Microdose framing uses sub-clinical doses — lower weight-loss efficacy than standard GLP-1 protocols
- Quarterly commitment only — 3-month minimum, paid upfront ($501–$540/quarter); no monthly flexibility
- State availability not publicly listed; 'eligible U.S. states' with no specific state list
- Labs not included; baseline bloodwork protocol not disclosed on any public page
- Compounding pharmacy not named; no 503A/503B accreditation details disclosed
Graded #453 · C
Strengths
- Unusually broad GLP-1 lineup — compounded semaglutide and tirzepatide in both oral tablets and injection, plus microdosing and longevity add-ons
- Online process with licensed-provider oversight, virtual consults, progress tracking and home delivery
- Oral tablet options for people who would rather not inject
Where it loses points
- Prices are not shown publicly — you only see costs after creating an account, so you cannot compare value upfront
- Labels its oral semaglutide 'research-grade' — wording usually tied to research/non-prescription peptides; confirm it is prescribed for human use
- Does not name its compounding pharmacy or list the states it serves; the listed address is a private mailbox (PMB), not a clinic
- Compounded GLP-1 only — no brand-name or insurance options; small, lightly documented operation
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.